CORESTEMCHEMON Inc. Logo

CORESTEMCHEMON Inc.

Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.

166480 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로255번길 24 (삼평동), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CORESTEMCHEMON Inc. is a biotechnology corporation operating through two primary divisions: Bio-pharmaceuticals and a Nonclinical Contract Research Organization (CRO). The Bio-pharmaceutical division focuses on developing novel stem cell therapies for intractable conditions, with clinical trials targeting neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), multiple sclerosis, and cerebellar ataxia, as well as autoimmune disorders such as systemic lupus erythematosus (SLE). The Nonclinical CRO division provides essential preclinical services, conducting toxicity and efficacy evaluations for a wide range of clients in the pharmaceutical, biopharmaceutical, medical device, and cosmetic industries.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for CORESTEMCHEMON Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 8.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 38.9 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 291.4 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 44.4 KB
2025-09-08 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.5 MB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.8 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.4 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.0 MB

Automate Your Workflow. Get a real-time feed of all CORESTEMCHEMON Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CORESTEMCHEMON Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea 229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark NOVO
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary NUTEX
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.